Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 2000 Aug;53(8):573–580. doi: 10.1136/jcp.53.8.573

Thrombophilia in pregnancy

I Walker 1
PMCID: PMC1762918  PMID: 11002758

Abstract

Thrombophilia can be defined as a predisposition to thrombosis. Abnormalities in haemostasis that are associated with clinical thrombophilia include heritable defects, such as mutations in the genes encoding the natural anticoagulants antithrombin, protein C, and protein S, or clotting factors prothrombin and factor V, and acquired defects, such as antiphospholipids. Women with thrombophilic defects have been shown to be at increased risk, not only of pregnancy associated thromboembolism, but also of other vascular complications of pregnancy, including pre-eclampsia and fetal loss. Routine thrombophilia screening of all women attending antenatal clinics is not recommended. Because some thrombophilic defects—for example, type 1 antithrombin deficiency and antiphospholipids—are associated with a high risk of recurrent thrombosis or other pregnancy complications, it is suggested that selected women (those with a personal or confirmed family history of venous thromboembolism or with a history of recurrent fetal loss) are screened for these defects to allow pregnancy management planning.

Key Words: thrombophilia • pregnancy

Full Text

The Full Text of this article is available as a PDF (129.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertina R. M., Koeleman B. P., Koster T., Rosendaal F. R., Dirven R. J., de Ronde H., van der Velden P. A., Reitsma P. H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 May 5;369(6475):64–67. doi: 10.1038/369064a0. [DOI] [PubMed] [Google Scholar]
  2. Bertina R. M., Reitsma P. H., Rosendaal F. R., Vandenbroucke J. P. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost. 1995 Jul;74(1):449–453. [PubMed] [Google Scholar]
  3. Bokarewa M. I., Bremme K., Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol. 1996 Feb;92(2):473–478. doi: 10.1046/j.1365-2141.1996.d01-1496.x. [DOI] [PubMed] [Google Scholar]
  4. Brenner B., Lanir N., Thaler I. HELLP syndrome associated with factor V R506Q mutation. Br J Haematol. 1996 Mar;92(4):999–1001. doi: 10.1046/j.1365-2141.1996.410947.x. [DOI] [PubMed] [Google Scholar]
  5. Clark P., Brennand J., Conkie J. A., McCall F., Greer I. A., Walker I. D. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost. 1998 Jun;79(6):1166–1170. [PubMed] [Google Scholar]
  6. Clifford K., Rai R., Watson H., Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod. 1994 Jul;9(7):1328–1332. doi: 10.1093/oxfordjournals.humrep.a138703. [DOI] [PubMed] [Google Scholar]
  7. Comp P. C., Thurnau G. R., Welsh J., Esmon C. T. Functional and immunologic protein S levels are decreased during pregnancy. Blood. 1986 Oct;68(4):881–885. [PubMed] [Google Scholar]
  8. Conard J., Horellou M. H., Van Dreden P., Lecompte T., Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 1990 Apr 12;63(2):319–320. [PubMed] [Google Scholar]
  9. Cook C. L., Pridham D. D. Recurrent pregnancy loss. Curr Opin Obstet Gynecol. 1995 Oct;7(5):357–366. [PubMed] [Google Scholar]
  10. Cook G., Walker I. D., McCall F., Conkie J. A., Greer I. A. Familial thrombophilia and activated protein C resistance: thrombotic risk in pregnancy? Br J Haematol. 1994 Aug;87(4):873–875. doi: 10.1111/j.1365-2141.1994.tb06757.x. [DOI] [PubMed] [Google Scholar]
  11. Cumming A. M., Tait R. C., Fildes S., Yoong A., Keeney S., Hay C. R. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995 Jul;90(3):725–727. doi: 10.1111/j.1365-2141.1995.tb05610.x. [DOI] [PubMed] [Google Scholar]
  12. D'Angelo A., Selhub J. Homocysteine and thrombotic disease. Blood. 1997 Jul 1;90(1):1–11. [PubMed] [Google Scholar]
  13. Dahlbäck B., Carlsson M., Svensson P. J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1004–1008. doi: 10.1073/pnas.90.3.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. De Stefano V., Leone G., Mastrangelo S., Tripodi A., Rodeghiero F., Castaman G., Barbui T., Finazzi G., Bizzi B., Mannucci P. M. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost. 1994 Jun;71(6):799–800. [PubMed] [Google Scholar]
  15. De Wolf F., Carreras L. O., Moerman P., Vermylen J., Van Assche A., Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol. 1982 Apr 1;142(7):829–834. doi: 10.1016/s0002-9378(16)32527-3. [DOI] [PubMed] [Google Scholar]
  16. Demers C., Ginsberg J. S., Hirsh J., Henderson P., Blajchman M. A. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med. 1992 May 1;116(9):754–761. doi: 10.7326/0003-4819-116-9-754. [DOI] [PubMed] [Google Scholar]
  17. Dizon-Townson D. S., Kinney S., Branch D. W., Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol. 1997 Oct;34(3):217–223. doi: 10.1016/s0165-0378(97)00039-9. [DOI] [PubMed] [Google Scholar]
  18. Dizon-Townson D. S., Nelson L. M., Easton K., Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol. 1996 Oct;175(4 Pt 1):902–905. doi: 10.1016/s0002-9378(96)80022-6. [DOI] [PubMed] [Google Scholar]
  19. Faioni E. M., Valsecchi C., Palla A., Taioli E., Razzari C., Mannucci P. M. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost. 1997 Nov;78(5):1343–1346. [PubMed] [Google Scholar]
  20. Finazzi G., Brancaccio V., Moia M., Ciaverella N., Mazzucconi M. G., Schinco P. C., Ruggeri M., Pogliani E. M., Gamba G., Rossi E. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996 May;100(5):530–536. doi: 10.1016/s0002-9343(96)00060-5. [DOI] [PubMed] [Google Scholar]
  21. Finazzi G., Caccia R., Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost. 1987 Dec 18;58(4):1094–1094. [PubMed] [Google Scholar]
  22. Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G. J., den Heijer M., Kluijtmans L. A., van den Heuvel L. P. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111–113. doi: 10.1038/ng0595-111. [DOI] [PubMed] [Google Scholar]
  23. Ginsberg J. S., Brill-Edwards P., Johnston M., Denburg J. A., Andrew M., Burrows R. F., Bensen W., Cividino A., Long A. A. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood. 1992 Aug 15;80(4):975–980. [PubMed] [Google Scholar]
  24. Ginsberg J. S., Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 1998 Nov;114(5 Suppl):524S–530S. doi: 10.1378/chest.114.5_supplement.524s. [DOI] [PubMed] [Google Scholar]
  25. Ginsberg J. S., Kowalchuk G., Hirsh J., Brill-Edwards P., Burrows R. Heparin therapy during pregnancy. Risks to the fetus and mother. Arch Intern Med. 1989 Oct;149(10):2233–2236. [PubMed] [Google Scholar]
  26. Ginsberg J. S., Wells P. S., Brill-Edwards P., Donovan D., Moffatt K., Johnston M., Stevens P., Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995 Nov 15;86(10):3685–3691. [PubMed] [Google Scholar]
  27. Goddijn-Wessel T. A., Wouters M. G., van de Molen E. F., Spuijbroek M. D., Steegers-Theunissen R. P., Blom H. J., Boers G. H., Eskes T. K. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol. 1996 May;66(1):23–29. doi: 10.1016/0301-2115(96)02383-4. [DOI] [PubMed] [Google Scholar]
  28. Grandone E., Margaglione M., Colaizzo D., d'Addedda M., Cappucci G., Vecchione G., Sciannamé N., Pavone G., Di Minno G. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. 1997 May;77(5):822–824. [PubMed] [Google Scholar]
  29. Griffin J. H., Evatt B., Wideman C., Fernández J. A. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 1993 Oct 1;82(7):1989–1993. [PubMed] [Google Scholar]
  30. Heijboer H., Brandjes D. P., Büller H. R., Sturk A., ten Cate J. W. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990 Nov 29;323(22):1512–1516. doi: 10.1056/NEJM199011293232202. [DOI] [PubMed] [Google Scholar]
  31. Hellgren M., Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995 Jul;173(1):210–213. doi: 10.1016/0002-9378(95)90192-2. [DOI] [PubMed] [Google Scholar]
  32. Hellgren M., Tengborn L., Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest. 1982;14(2):127–141. doi: 10.1159/000299460. [DOI] [PubMed] [Google Scholar]
  33. Kang S. S., Wong P. W., Susmano A., Sora J., Norusis M., Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991 Mar;48(3):536–545. [PMC free article] [PubMed] [Google Scholar]
  34. Khamashta M. A., Cuadrado M. J., Mujic F., Taub N. A., Hunt B. J., Hughes G. R. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995 Apr 13;332(15):993–997. doi: 10.1056/NEJM199504133321504. [DOI] [PubMed] [Google Scholar]
  35. Koster T., Blann A. D., Briët E., Vandenbroucke J. P., Rosendaal F. R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995 Jan 21;345(8943):152–155. doi: 10.1016/s0140-6736(95)90166-3. [DOI] [PubMed] [Google Scholar]
  36. Koster T., Rosendaal F. R., Briët E., van der Meer F. J., Colly L. P., Trienekens P. H., Poort S. R., Reitsma P. H., Vandenbroucke J. P. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood. 1995 May 15;85(10):2756–2761. [PubMed] [Google Scholar]
  37. Koster T., Rosendaal F. R., de Ronde H., Briët E., Vandenbroucke J. P., Bertina R. M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993 Dec 18;342(8886-8887):1503–1506. doi: 10.1016/s0140-6736(05)80081-9. [DOI] [PubMed] [Google Scholar]
  38. Kupferminc M. J., Eldor A., Steinman N., Many A., Bar-Am A., Jaffa A., Fait G., Lessing J. B. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999 Jan 7;340(1):9–13. doi: 10.1056/NEJM199901073400102. [DOI] [PubMed] [Google Scholar]
  39. Kutteh W. H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996 May;174(5):1584–1589. doi: 10.1016/s0002-9378(96)70610-5. [DOI] [PubMed] [Google Scholar]
  40. Letsky E., de Swiet M. Annotation. Thromboembolism in pregnancy and its management. Br J Haematol. 1984 Aug;57(4):543–552. [PubMed] [Google Scholar]
  41. Long A. A., Ginsberg J. S., Brill-Edwards P., Johnston M., Turner C., Denburg J. A., Bensen W. G., Cividino A., Andrew M., Hirsh J. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost. 1991 Nov 1;66(5):520–524. [PubMed] [Google Scholar]
  42. Love P. E., Santoro S. A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990 May 1;112(9):682–698. doi: 10.7326/0003-4819-112-9-682. [DOI] [PubMed] [Google Scholar]
  43. Lowe G. D., Rumley A., Woodward M., Reid E., Rumley J. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables. Thromb Haemost. 1999 Jun;81(6):918–924. [PubMed] [Google Scholar]
  44. Malm J., Laurell M., Dahlbäck B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol. 1988 Apr;68(4):437–443. doi: 10.1111/j.1365-2141.1988.tb04232.x. [DOI] [PubMed] [Google Scholar]
  45. Mateo J., Oliver A., Borrell M., Sala N., Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997 Mar;77(3):444–451. [PubMed] [Google Scholar]
  46. Mathonnet F., de Mazancourt P., Bastenaire B., Morot M., Benattar N., Beufé S., Borg J. Y., Giudicelli Y. Activated protein C sensitivity ratio in pregnant women at delivery. Br J Haematol. 1996 Jan;92(1):244–246. doi: 10.1046/j.1365-2141.1995.00271.x. [DOI] [PubMed] [Google Scholar]
  47. McColl M. D., Ramsay J. E., Tait R. C., Walker I. D., McCall F., Conkie J. A., Carty M. J., Greer I. A. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997 Oct;78(4):1183–1188. [PubMed] [Google Scholar]
  48. Nagy B., Tóth T., Rigó J., Jr, Karádi I., Romics L., Papp Z. Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women. Clin Genet. 1998 Jun;53(6):478–481. doi: 10.1111/j.1399-0004.1998.tb02599.x. [DOI] [PubMed] [Google Scholar]
  49. Nordström M., Lindblad B., Bergqvist D., Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992 Aug;232(2):155–160. doi: 10.1111/j.1365-2796.1992.tb00565.x. [DOI] [PubMed] [Google Scholar]
  50. Olivieri O., Friso S., Manzato F., Guella A., Bernardi F., Lunghi B., Girelli D., Azzini M., Brocco G., Russo C. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol. 1995 Oct;91(2):465–470. doi: 10.1111/j.1365-2141.1995.tb05323.x. [DOI] [PubMed] [Google Scholar]
  51. Pabinger I., Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):742–748. doi: 10.1161/01.atv.16.6.742. [DOI] [PubMed] [Google Scholar]
  52. Poort S. R., Rosendaal F. R., Reitsma P. H., Bertina R. M. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996 Nov 15;88(10):3698–3703. [PubMed] [Google Scholar]
  53. Preston F. E., Rosendaal F. R., Walker I. D., Briët E., Berntorp E., Conard J., Fontcuberta J., Makris M., Mariani G., Noteboom W. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996 Oct 5;348(9032):913–916. doi: 10.1016/s0140-6736(96)04125-6. [DOI] [PubMed] [Google Scholar]
  54. Rai R. S., Clifford K., Cohen H., Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995 Dec;10(12):3301–3304. doi: 10.1093/oxfordjournals.humrep.a135907. [DOI] [PubMed] [Google Scholar]
  55. Rai R. S., Regan L., Clifford K., Pickering W., Dave M., Mackie I., McNally T., Cohen H. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod. 1995 Aug;10(8):2001–2005. doi: 10.1093/oxfordjournals.humrep.a136224. [DOI] [PubMed] [Google Scholar]
  56. Rai R., Cohen H., Dave M., Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) BMJ. 1997 Jan 25;314(7076):253–257. doi: 10.1136/bmj.314.7076.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Rees D. C., Cox M., Clegg J. B. World distribution of factor V Leiden. Lancet. 1995 Oct 28;346(8983):1133–1134. doi: 10.1016/s0140-6736(95)91803-5. [DOI] [PubMed] [Google Scholar]
  58. Ridker P. M., Hennekens C. H., Lindpaintner K., Stampfer M. J., Eisenberg P. R., Miletich J. P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995 Apr 6;332(14):912–917. doi: 10.1056/NEJM199504063321403. [DOI] [PubMed] [Google Scholar]
  59. Ridker P. M., Miletich J. P., Buring J. E., Ariyo A. A., Price D. T., Manson J. E., Hill J. A. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med. 1998 Jun 15;128(12 Pt 1):1000–1003. doi: 10.7326/0003-4819-128-12_part_1-199806150-00007. [DOI] [PubMed] [Google Scholar]
  60. Ridker P. M., Miletich J. P., Hennekens C. H., Buring J. E. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997 Apr 23;277(16):1305–1307. [PubMed] [Google Scholar]
  61. Rosendaal F. R., Koster T., Vandenbroucke J. P., Reitsma P. H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood. 1995 Mar 15;85(6):1504–1508. [PubMed] [Google Scholar]
  62. Rosendaal F. R. Risk factors for venous thrombotic disease. Thromb Haemost. 1999 Aug;82(2):610–619. [PubMed] [Google Scholar]
  63. Rotmensch S., Liberati M., Mittlemann M., Ben-Rafael Z. Activated protein C resistance and adverse pregnancy outcome. Am J Obstet Gynecol. 1997 Jul;177(1):170–173. doi: 10.1016/s0002-9378(97)70457-5. [DOI] [PubMed] [Google Scholar]
  64. Sanson B. J., Friederich P. W., Simioni P., Zanardi S., Hilsman M. V., Girolami A., ten Cate J. W., Prins M. H. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost. 1996 Mar;75(3):387–388. [PubMed] [Google Scholar]
  65. Sanson B. J., Lensing A. W., Prins M. H., Ginsberg J. S., Barkagan Z. S., Lavenne-Pardonge E., Brenner B., Dulitzky M., Nielsen J. D., Boda Z. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999 May;81(5):668–672. [PubMed] [Google Scholar]
  66. Simioni P., Prandoni P., Burlina A., Tormene D., Sardella C., Ferrari V., Benedetti L., Girolami A. Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost. 1996 Dec;76(6):883–886. [PubMed] [Google Scholar]
  67. Simioni P., Prandoni P., Zanon E., Saracino M. A., Scudeller A., Villalta S., Scarano L., Girolami B., Benedetti L., Girolami A. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost. 1996 Aug;76(2):187–189. [PubMed] [Google Scholar]
  68. Tait R. C., Walker I. D., Perry D. J., Islam S. I., Daly M. E., McCall F., Conkie J. A., Carrell R. W. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994 May;87(1):106–112. doi: 10.1111/j.1365-2141.1994.tb04878.x. [DOI] [PubMed] [Google Scholar]
  69. Tait R. C., Walker I. D., Reitsma P. H., Islam S. I., McCall F., Poort S. R., Conkie J. A., Bertina R. M. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995 Jan;73(1):87–93. [PubMed] [Google Scholar]
  70. Thaler E., Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol. 1981 Jun;10(2):369–390. [PubMed] [Google Scholar]
  71. Toglia M. R., Weg J. G. Venous thromboembolism during pregnancy. N Engl J Med. 1996 Jul 11;335(2):108–114. doi: 10.1056/NEJM199607113350207. [DOI] [PubMed] [Google Scholar]
  72. Triplett D. A., Harris E. N. Antiphospholipid antibodies and reproduction. Am J Reprod Immunol. 1989 Nov-Dec;21(3-4):123–131. doi: 10.1111/j.1600-0897.1989.tb01016.x. [DOI] [PubMed] [Google Scholar]
  73. Ubbink J. B., Vermaak W. J., van der Merwe A., Becker P. J. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993 Jan;57(1):47–53. doi: 10.1093/ajcn/57.1.47. [DOI] [PubMed] [Google Scholar]
  74. Williamson D., Brown K., Luddington R., Baglin C., Baglin T. Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C. Blood. 1998 Feb 15;91(4):1140–1144. [PubMed] [Google Scholar]
  75. Zöller B., Svensson P. J., He X., Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994 Dec;94(6):2521–2524. doi: 10.1172/JCI117623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. de Visser M. C., Rosendaal F. R., Bertina R. M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 1999 Feb 15;93(4):1271–1276. [PubMed] [Google Scholar]
  77. de Vries J. I., Dekker G. A., Huijgens P. C., Jakobs C., Blomberg B. M., van Geijn H. P. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol. 1997 Nov;104(11):1248–1254. doi: 10.1111/j.1471-0528.1997.tb10970.x. [DOI] [PubMed] [Google Scholar]
  78. den Heijer M., Koster T., Blom H. J., Bos G. M., Briet E., Reitsma P. H., Vandenbroucke J. P., Rosendaal F. R. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996 Mar 21;334(12):759–762. doi: 10.1056/NEJM199603213341203. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES